Analysis Group Co-investigates the Impact of Berotralstat on Health Care Resource Utilization Among Patients with Hereditary Angioedema in JMCP Article
June 3, 2025
Hereditary angioedema (HAE) is a rare disorder marked by painful, recurring attacks of tissue swelling that can be life-threatening if they result in airway obstruction. An oral long-term prophylaxis (LTP) treatment – berotralstat – has been clinically proven to mitigate HAE symptoms, which could lead to a reduction in the health care resource utilization (HRU) of patients with the disorder. However, the extent to which berotralstat impacts the HRU of patients with HAE had remained an open research question.
To bridge this gap, an Analysis Group team led by Principal François Laliberté and Manager Sean MacKnight worked with researchers from BioCryst, the University of California San Diego, and Veterans Administration Healthcare on a first-of-its-kind study comparing rates of medical visits and hospitalizations among patients with HAE before and after initiation of berotralstat on a per-patient, per-year basis. In an article on their findings, the authors report that such visits and hospitalizations decreased significantly following treatment initiation. They conclude, “these results suggest that berotralstat LTP initiation promotes measurable clinical benefits for patients with HAE, as well as for the healthcare system overall through significant declines in HRU.”
The article, “Reductions in medical visits and hospitalizations following berotralstat initiation in patients with hereditary angioedema in the United States,” was published in the Journal of Managed Care and Specialty Pharmacy.